CADTH Resumes Scientific Advice Activities
CADTH just announced that they have resumed activities in their Scientific Advice Program and are once again accepting applications for [...]
NICE Seeks to Simplify Selection Process for Drug and Medical Device Evaluation
NICE is seeking public input on changing the process it uses to selects the topics it develops guidance on. The [...]
The Trouble With List Prices
This week, the RAND Corporation issued a new report highlighting that US list prices on insulin are 8.1 times higher than [...]
ICER Launches Customizable COVID-19 Cost-Effectiveness Model
The Institute for Clinical and Economic Review (ICER) announced the launch of a cloud-based platform that allows customization of model [...]
ConcertAI Launches CancerLinQ, An Oncology-focused Set of COVID-19 Resources
ConcertAI recently launched CancerLinQ Discovery, a set of oncology-focused COVID-19 resources aimed at supporting the needs of providers, innovators, and [...]
AstraZeneca Walks Back On its COVID-19 ‘No-Profit’ Pledge
Among the many pharma companies racing to develop a safe, effective vaccine for COVID-19, AstraZeneca stands out for its pledge [...]
Increasing Transparency in HEOR Through the Real-World Evidence (RWE) Transparency Initiative
Due to the funding or execution of studies by industry stakeholders and disagreements over methodological approaches, establishing and maintaining trust [...]
Dr. William Morice on Applying RWE to COVID-19 diagnostics
One of the most critical pieces of the COVID-19 puzzle is diagnostic testing that enables rapid diagnosis and treatment of [...]
PCORI’s Research Scope Expanded to Include Cost Outcomes
The Patient-Centered Outcomes Research Institute (PCORI) was created by the Affordable Care Act (ACA) in 2010. Since then, the institute [...]
Access Market Intelligence’s Specialty Pharmacy Database Now Available
Access Market Intelligence recently released its Specialty Pharmacy Database (SPD) which provides the industry’s most comprehensive, continually updated database on [...]
AMCP CEO Susan Cantrell Comments On Supreme Court Case
In commenting on Rutledge v. The Pharmaceutical Care Management Association, scheduled to be argued before the US Supreme Court yesterday, [...]
Enhancing RWE through Natural History Studies
Deploying RWE-analyses is not just a simple matter of having sufficient statistical knowledge. There are a variety of RWE methodologies [...]
Despite Limitations, Claims Data Still Useful in Fight Against COVID-19
The use of healthcare claims data in studying infectious disease has historically been rather limited. There are many other sources [...]
AMCP 2021’s Call for Poster Abstracts Now Open
AMCP invites submissions for abstracts to be presented at AMCP 2021 in the spring. Don’t miss your chance to share [...]
How Will Innovation Value be Redefined in 2021?
The health policy landscape will most certainly be altered in 2021 as a result of the US Presidential election. No [...]
Personalized Medicine Coalition Takes Aim at Setting Patient-centered Research Agenda
The Personalized Medicine Coalition (PMC) released a new patient-centered research agenda for personalized medicine defining 45 research questions across nine [...]
[Webinar] Cannabis Research to Reinforce Formulary Coverage Decisions
Cannabis as medicine has generated a tremendous amount of interest in the scientific community. It has also generated a tremendous [...]
COVID-19 and Prescription Utilization
The stay-at-home orders and economic uncertainty brought about by COVID-19 has impacted medication adherence and how patients manage their health. [...]
How HEOR Professionals Can Be Force Multipliers in the Fight Against COVID-19
US President Donald Trump and First Lady Melania Trump join the growing ranks of world leaders infected by COVID-19. It [...]
Onshoring Essential Drug Manufacturing is a Matter of National Security
Recently, FDA Commissioner Stephen Hahn and Deputy Commissioner Anand Shah wrote an op-ed stating that the COVID-19 pandemic exposed the [...]
ICER Weighs in on Fair Access to Prescription Drugs
Independent nonprofit Institute for Clinical and Economic Review (ICER) published a new white paper entitled “Cornerstones of ‘Fair’ Drug Coverage: [...]
Good Data Holds Tremendous Value for Patients
Innovative use of good data can lead to better patient care pathways and models of care. Collecting, collating, and assessing [...]
AMCP Partnership Forum: New Specialty Medication Benefit and Reimbursement Designs
One of the biggest challenges facing patients and payers is the rising cost of specialty drugs including gene therapies and [...]
How Government Permits Cross-subsidies to Inflate Healthcare Costs
Government often permits companies to overcharge one set of consumers in order to subsidize other consumers in a market-distorting phenomenon [...]
Syapse and FDA Leverage Real-World Data to Study Impact of COVID-19 on Cancer Patients
According to the National Cancer Institute, the COVID-19 pandemic has resulted in delays for cancer screening, diagnosis, and treatment, leading [...]